On April 30, 2018, the Food and Drug Administration granted regular approval to dabrafenib (Tafinlar, Novartis Pharmaceuticals Corp.) and trametinib (Mekinist, Novartis Pharmaceuticals Corp.) in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.
Read the full FDA announcement here.
Posted 5/1/2018
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
